Dorzopt Plus eye drops 20mg/ml + 5mg/ml, 5ml

Dorzopt Plus (Dorsopt plus) eye drops - refers to combination drugs that are used to treat glaucoma. The mechanism of reducing intraocular pressure is due to oppression of fluid production. The medicine is available in the form of eye drops.

The antiglaucoma preparation contains two active components: dorzolamide and timolol, each of which reduces the increased intraocular pressure by decreasing the secretion of the aqueous humor. Joint action of these substances in the combined preparation Dorzopt Plus leads to a more pronounced decrease in intraocular pressure.

Dorzolamide is a selective inhibitor of type II carbonic anhydrase. Inhibition of the carbonic anhydrase of the ciliary body leads to a decrease in the secretion of the aqueous humor, presumably due to a decrease in the formation of bicarbonate ions, which in turn leads to a slowdown in the transport of sodium and intraocular fluid.

Timolol is a non-selective beta-blocker. Although the exact mechanism of action of timolol in reducing intraocular pressure has not yet been established, a number of studies have shown a predominant decrease in the formation of intraocular fluid, as well as a slight increase in its outflow.

Decrease in intraocular pressure occurs 20 minutes after instillation, reaches a maximum after 2 hours and lasts at least 24 hours.

Pharmacokinetics

Dorzolamide

Suction and distribution

It penetrates the eye mainly through the cornea (to a lesser extent through the sclera or limbus). Systemic absorption is low. After entering the blood quickly penetrates into the red blood cells containing a significant amount of carbonic anhydrase II. Binding to plasma proteins - 33%.

Metabolism and excretion

It is transformed into an N-desethylated metabolite, less active with respect to carbonic anhydrase II, but capable of blocking carbonic anhydrase I. For long-term use, it accumulates in red blood cells. It is excreted by the kidneys in the unmodified form and in the form of metabolites. After withdrawal, the fast phase of withdrawal is replaced by a slow one, caused by the gradual release of dorzolamide from erythrocytes, with T1 / 2 about 4 months.

Timolol

When topical, timolol penetrates the systemic circulation. The concentration of timolol in the plasma was studied in 6 patients with topical administration of timolol in the form of eye drops 0.5% 2 times / day. Mean Cmax after morning use was 0.46 ng / ml, after application in the afternoon - 0.35 ng / ml.

Indications:

Increased intraocular pressure with:

• open-angle glaucoma;
• pseudoexfoliation glaucoma.

Contraindications:

• Hypersensitivity to the components of the drug;
• bronchial asthma (including in the anamnesis);
• severe chronic obstructive pulmonary disease (COPD);
• sinus bradycardia;
• AV blockade II and III degree;
• severe heart failure;
• cardiogenic shock;
• renal failure of severe degree (QC less than 30 ml / min);
• dystrophic processes in the cornea;
• pregnancy;
• lactation (breastfeeding);
• children and adolescents under 18 years of age (because efficiency and safety have not been adequately studied).

With caution: hepatic insufficiency, elderly age, diabetes mellitus.

Special instructions:

Before using Dorsopt Plus, you need to ensure adequate control of the cardiovascular system. Patients with a history of severe cardiac disease and signs of heart failure should be closely monitored.

Dorzopt Plus contains a preservative of benzalkonium chloride, which can precipitate in soft contact lenses and have a damaging effect on the eye tissue. Therefore, patients wearing soft contact lenses should remove them before applying drops and set back no earlier than 20 minutes after instillation.

Caution is prescribed to patients with diabetes mellitus, since beta-blockers may mask the symptoms of acute hypoglycemia.

Before the planned surgical operation, the drug should be gradually discontinued 48 hours before the general anesthesia. beta-blockers increase the effect of muscle relaxants and means for general anesthesia.

Impact on the ability to drive vehicles and other mechanisms that require increased concentration

During the period of treatment it is necessary to refrain from driving motor vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

Suggested Use:

Bury 1 drop in the conjunctival sac 2 times / day.

If several local ophthalmic medicines are used in the treatment, then their administration should occur at an interval of 10 minutes.

The duration of treatment is determined by the doctor depending on the clinical condition of the patient.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!